| PACK, 1996 | Ketanserin 40 mg / j pdt 1 mois 80 mg / j ensuite (n=1930) vs. Placebo (n=1969) | patients over 40 years old who had had documented intermittent claudication for at least two months and in whom the ratio of systolic blood pressure in the ankle to that in the arm was less than or equal to 0.85 in both arteries of at least one foot | double blind Parallel groups Sample size: 1930/1969 Primary endpoint: IDM, AVC majeur, amputation au dessus de la cheville pour des raisons autres que tumorales ou trauma FU duration: 1 y |
| Walden, 1991 | Ketanserin 60 mg / j pdt 1 mois 120 mg / j ensuite (n=17) vs. Placebo (n=18) | patients with intermittent claudication (stade II) | double blind Parallel groups Sample size: 17/18 Primary endpoint: Périmètre de marche FU duration: 15 months |
| Thulesius, 1987 | Ketanserin 60 mg / j pdt 2 semaines 120 mg / j ensuite (n=79) vs. Placebo (n=86) | patients with intermittent claudication (stade II) | double blind Parallel groups Sample size: 79/86 Primary endpoint: Périmètre de marche FU duration: 6 months |
